Commonwealth of Pennsylvania Public School Empls Retrmt SYS Sells 20,339 Shares of Abbott Laboratories $ABT

Key Points

• Pennsylvania’s public school employees’ retirement system reduced its Abbott Laboratories stake by 5%, selling 20,339 shares and retaining 384,719 shares valued at approximately $34.9 million. Institutional investors collectively own 75.18% of ABT.
• Abbott exceeded quarterly expectations with $1.31 EPS and $12.59 billion in revenue, while revenue increased 13% year over year. The company guided for fiscal 2026 EPS of $5.45–$5.60.
• Abbott declared a quarterly dividend of $0.63 per share, equivalent to a 2.3% annualized yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $118.67, though valuation remains a potential constraint.

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lessened its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 5.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 384,719 shares of the healthcare product maker's stock after selling 20,339 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS's holdings in Abbott Laboratories were worth $34,909,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Freemont Management S.A. increased its stake in shares of Abbott Laboratories by 197.2% in the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker's stock worth $1,341,000 after buying an additional 7,100 shares during the period. PFA Pension Forsikringsaktieselskab bought a new stake in Abbott Laboratories in the 4th quarter worth $116,580,000. Thrivent Financial for Lutherans increased its position in shares of Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker's stock valued at $30,931,000 after acquiring an additional 48,286 shares during the period. Aureus Asset Management LLC raised its stake in shares of Abbott Laboratories by 25.0% during the first quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker's stock valued at $34,078,000 after acquiring an additional 66,422 shares during the last quarter. Finally, Concurrent Investment Advisors LLC boosted its holdings in shares of Abbott Laboratories by 23.9% during the fourth quarter. Concurrent Investment Advisors LLC now owns 88,784 shares of the healthcare product maker's stock worth $11,124,000 after purchasing an additional 17,137 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $111.27 on Monday. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The stock has a market cap of $192.53 billion, a PE ratio of 36.01, a price-to-earnings-growth ratio of 2.15 and a beta of 0.59. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The company's fifty day moving average price is $97.67 and its 200-day moving average price is $99.77.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same period in the prior year, the firm earned $1.26 EPS. The company's revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories's dividend payout ratio (DPR) is currently 81.55%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ABT. Argus cut their target price on Abbott Laboratories from $140.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday, April 21st. TD Cowen reiterated a "buy" rating and issued a $115.00 price objective on shares of Abbott Laboratories in a report on Friday, July 17th. Citigroup lifted their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a "buy" rating in a research note on Friday, July 17th. BTIG Research raised their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a "buy" rating in a report on Friday, July 17th. Finally, UBS Group cut their price objective on Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a research report on Tuesday, July 28th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $118.67.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Alphabet AI partnership expands Abbott’s growth opportunity: Abbott and Alphabet announced a multiyear collaboration integrating data from Abbott’s over-the-counter Lingo continuous glucose monitor into the Google Health app. Google’s AI Health Coach is expected to use the data to provide personalized recommendations, potentially increasing Lingo adoption and strengthening Abbott’s position in consumer digital health. Can Abbott Laboratories’ Lingo Partnership With Alphabet Unlock a New Era of AI-Powered Health?
• Positive Sentiment: Wolfe Research upgraded ABT to Outperform: The firm raised its rating from “Peer Perform” and set a $130 price target, implying substantial upside from recent trading levels. The upgrade indicates improving analyst confidence in Abbott’s earnings durability and growth prospects.
• Positive Sentiment: Established Pharmaceuticals remains a growth driver: Abbott’s Established Pharmaceutical Products division is benefiting from emerging-market demand, a broad branded-generics portfolio and biosimilar opportunities. This provides diversification beyond the company’s medical-device businesses. What’s Backing Abbott’s Established Pharmaceuticals Division Growth
• Neutral Sentiment: Recent trading strength reflects broad investor support: Abbott outperformed some medical-product peers during a recent strong market session, while bullish commentary has highlighted the company’s diversified portfolio and long-term growth potential. Abbott Laboratories Stock Outperforms Competitors on Strong Trading Day
• Negative Sentiment: Valuation remains a potential constraint: With a forward-looking earnings multiple above 36 and the stock already well above its recent moving averages, further gains may require continued earnings execution and evidence that newer initiatives such as Lingo can materially contribute to revenue.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source